Evidence map›Paper›PMID 32025858›Full record

ReviewSurgery today2020

Clinical implications of cancer stem cells in digestive cancers: acquisition of stemness and prognostic impact.

Ryouichi Tsunedomi, Kiyoshi Yoshimura, Nobuaki Suzuki, Shoichi Hazama, Hiroaki Nagano

Abstract readReview
PubMed Publisher
In one paragraph

Review in Surgery today, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Pleiotropic effects of DCLK1 in cancer and cancer stem cells.Frontiers in molecular biosciences · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ryouichi TsunedomiDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. tsune-r@yamaguchi-u.ac.jp.ORCID http://orcid.org/0000-0003-4251-1936
Kiyoshi YoshimuraShowa University Clinical Research Institute for Clinical Pharmacology and Therapeutics, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan.
Nobuaki SuzukiDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Shoichi HazamaDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Hiroaki NaganoDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Yamaguchi University · JPShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digestive system cancers are the most frequent cancers worldwide and often associated with poor prognosis because of their invasive and metastatic characteristics. Recent studies have found that the plasticity of cancer cells can impart cancer stem-like properties via the epithelial-mesenchymal transition (EMT). Cancer stem-like properties such as tumor initiation are integral to the formation of metastasis, which is the main cause of poor prognosis. Numerous markers of cancer stem cells (CSCs) have been identified in many types of cancer. Therefore, CSCs, via their stem cell-like functions, may play an important role in prognosis after surgery. While several reports have described prognostic analysis using CSC markers, few reviews have summarized CSCs and their association with prognosis. Herein, we review the prognostic potential of eight CSC markers, CD133, CD44, CD90, ALDH1A1, EPCAM, SOX2, SOX9, and LGR5, in digestive cancers including those of the pancreas, colon, liver, gastric, and esophagus.

Indexed as

AC133 AntigenAldehyde Dehydrogenase 1 FamilyBiomarkers, TumorDigestive System NeoplasmsEpithelial Cell Adhesion MoleculeGene ExpressionGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsNeoplastic Stem CellsPrognosisReceptors, G-Protein-CoupledRetinal DehydrogenaseSOX9 Transcription FactorSOXB1 Transcription FactorsSurvival RateAC133 AntigenAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanBiomarkers, TumorCD44 protein, humanEPCAM protein, humanEpithelial Cell Adhesion MoleculeHyaluronan ReceptorsLGR5 protein, humanPROM1 protein, humanReceptors, G-Protein-CoupledRetinal DehydrogenaseSOX2 protein, humanSOX9 protein, humanSOX9 Transcription FactorSOXB1 Transcription FactorsThy-1 AntigensCancer stem cellDigestive cancerPrognosis

Identifiers

PMID32025858
OpenAlexW3005524217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.